Overview

Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a doble blind, placebo controlled clinical trial to assess safety and efficacy of intravenous administration of Umbilical cord-derived Mesenchymal Stem cells in patients with ischemic stroke within 6 months of onset.
Phase:
Phase 2
Details
Lead Sponsor:
General Hospital of Shenyang Military Region